Welcome to the 4th Novel Conjugates Summit!

We are witnessing a surging 83% growth of novel drug conjugates, with major collaborations between Nurix and Pfizer for antibody-degrader conjugates and Bicycle and Novartis for radiopharmaceuticals. With investments booming in bispecific ADCs, peptide drug conjugates and oligonucleotide conjugates, the charge is on to make iterative and incremental improvements to ADCs to pave the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs.

Encompassing the landscape of these new frontiers in targeted cancer therapy, the 4th Novel Conjugates Summit is returning as a one-stop shop to shine a spotlight on which novel approaches are currently being explored, what benefit each approach has, and provide a comprehensive assessment on how you can widen your conjugate design toolkit.

Join us next March to find the next hottest conjugate approach as we delve into emerging data and industry-leading discussions around novel bioconjugate design and development to redefine the future of targeted cancer therapies.

URLs:

Brochure: https://go.evvnt.com/2739582-0?pid=91

Tickets: https://go.evvnt.com/2739582-2?pid=91

Prices:

Drug Developer Conference + Workshop Day: USD 4197.00,

Drug Developer Conference Only: USD 2999.00,

Academic Conference + Workshop Day: USD 3597.00,

Academic Conference Only: USD 2599.00,

Service Provider Conference + Workshop Day: USD 5097.00,

Service Provider Conference Only: USD 3699.00

Speakers: Akihiko Yamamoto, Senior Director, Eisai, Andrew Buesking, Senior Director,  Prelude Therapeutics​, Arnaud Tiberghien, Associate Director, Bicycle Therapeutics, Arne Scheu, CEO, Valink Therapeutics, Caitlyn Miller, Co-Founder and CEO, TwoStep Therapeutics, Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies Inc., Christopher Leamon, Chief Scientific Officer, Fusion Pharmaceuticals, David White, Senior Vice President and Head of Drug Discovery, ProteinQure, **** Xu, Senior Vice President, Head of Biostatistics and Data Management, OBI Pharma Inc., Gwenn Hansen, Chief Scientific Officer,  Nurix Therapeutics, Hadi Falahatpisheh, Vice President - Research and Development, ALX Oncology Inc., Hong Wan, President, Chief Executive Officer and Co-Founder, Tallac Therapeutics, J Cory Kalvass, Research Fellow, AbbVie, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences Inc., Jijun ****, Chief Scientific Officer, Salubris Biotherapeutics Inc., Kevin Hamblett, Senior Director, ADC Biology, Pfizer, Leo Qian, Co-Founder and Vice President - Discovery Research, Entrada Therapeutics Inc., Marc-Andre Kasper, Vice President Chemistry and Early Discovery, Tubulis GmbH, Oliver Schon, VP, Research and Development, BiVictriX Therapeutics Ltd, Qinsi Zheng, Principal Scientist, Orum Therapeutics, Stanley Lewis, Founder and Chief Executive Officer, A28 Therapeutics, Thomas Natoli, Senior Director, Dyne Therapeutics, Vicky Appleman, Associate Director, Oncology Drug Discovery, Takeda Pharmaceutical Co. Ltd., Vijaya Pattabiraman, Co-Founder and Chief Technology Officer, Bright Peak Therapeutics, Vimal Patel, Vice President - Chemistry, Manufacturing and Controls, RadioPharm Theranostics